ID: ALA5201646

Max Phase: Preclinical

Molecular Formula: C14H16N6OS

Molecular Weight: 316.39

Representations

Canonical SMILES:  CCc1cc(=O)n2nc(NCCNc3ccccn3)sc2n1

Standard InChI:  InChI=1S/C14H16N6OS/c1-2-10-9-12(21)20-14(18-10)22-13(19-20)17-8-7-16-11-5-3-4-6-15-11/h3-6,9H,2,7-8H2,1H3,(H,15,16)(H,17,19)

Standard InChI Key:  QONVAYXHZABMBX-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 316.39

Molecular Weight (Monoisotopic): 316.1106

AlogP: 1.63

#Rotatable Bonds: 6

Polar Surface Area: 84.21

Molecular Species: NEUTRAL

HBA: 8

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 5.08

CX LogP: 2.15

CX LogD: 2.15

Aromatic Rings: 3

Heavy Atoms: 22

QED Weighted: 0.67

Np Likeness Score: -2.51

References

1. Bayrak A, Mohr F, Kolb K, Szpakowska M, Shevchenko E, Dicenta V, Rohlfing AK, Kudolo M, Pantsar T, Günther M, Kaczor AA, Poso A, Chevigné A, Pillaiyar T, Gawaz M, Laufer SA..  (2022)  Discovery and Development of First-in-Class ACKR3/CXCR7 Superagonists for Platelet Degranulation Modulation.,  65  (19.0): [PMID:36150079] [10.1021/acs.jmedchem.2c01198]

Source

Source(1):

• Scientific Literature